FindMyKOL
Clinical trialNCT05464719RecruitingPhase 2Interventional

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

NCT05464719 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is recruiting participants. It studies Loncastuximab tesirine in Large B-cell Lymphoma and Lymphoma. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 23 Sept 2022 and a primary completion date of 30 Jan 2030.

SponsorM.D. Anderson Cancer CenterEnrollment30Large B-cell LymphomaLymphoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05464719
FieldValue
Registry IDNCT05464719
StatusRecruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorM.D. Anderson Cancer Center
Enrollment30
Registered sites1
Countries1
ConditionsLarge B-cell Lymphoma and Lymphoma
DrugsLoncastuximab tesirine
Start23 Sept 2022
Primary completion30 Jan 2030
Study completion30 Jan 2030
Last update posted15 Jul 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Texas, United States1 site, 1 recruiting
  • Md Anderson Cancer Center

    Houston

    Paolo Strati, MD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 site, 1 recruitingTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05464719

Each answer restates registry values shown on this page.

What is NCT05464719?

NCT05464719 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Loncastuximab tesirine in Large B-cell Lymphoma and Lymphoma.

Is NCT05464719 recruiting?

As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT05464719?

The registry names Paolo Strati, MD (principal investigator, M.D. Anderson Cancer Center) as the overall official.

Where does NCT05464719 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05464719 study?

The registered drug and biological interventions are Loncastuximab tesirine.

When is NCT05464719 expected to complete?

The registry lists a primary completion date of 30 Jan 2030 and a study completion date of 30 Jan 2030. The sponsor last updated the record on 15 Jul 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.